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Total Body Irradiation for Pretransplantation
Conditioning in Acute Lymphoblastic Leukemia:
Excellent Outcomes in All but Older Patients with
Comorbidities
Andrew Daly,1 Mary L. Savoie,1 Michelle Geddes,1 Ahsan Chaudhry,1 Douglas Stewart,1
Peter Duggan,1 Nizar Bahlis,1 Jan Storek,1 Chris Brown,1 Mona Shafey,1
A. Robert Turner,2 James Russell1Hematopoietic stem cell transplantation (SCT) is routinely offered to suitable candidates with high-risk or
advanced acute lymphoblastic leukemia (ALL). In this report, we update our experience with SCT in patients
with ALL with a novel conditioning regimen. A total of 44 patients with high-risk or advanced (greater than
first complete remission) ALL in remission underwent SCT after myeloablative conditioning with
fludarabine 1 busulfan 1 total body irradiation. The median follow-up of surviving patients was 4.3 years
(range, 1.0-9.0 years). The cohort consists of 32 patients with high-risk disease (median age, 40 years; range,
19-64 years) and 12 patients with advanced disease (median age, 25 years; range, 19-65 years) who under-
went SCT: 25 with a related donor (21 fully matched) and 19 with an unrelated donor (16 fully matched). The
cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD)was 53.2%, and that of grade III-IV
acute GVHD was 20.6%. The incidence of chronic GVHD was 55%. The 100-day nonrelapse mortality was
13.6%. Five-year progression-free survival was 56.7%, and 5-year overall survival was 66.0%. Nine patients
(20%) died in remission, 6 (14%) died after relapse, and 2 survived after a second SCT for relapsed disease.
Outcomes were inferior in older patients with comorbidities compared with other patients.
Biol Blood Marrow Transplant 18: 1921-1926 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Stem cell transplantation, Conditioning, Age, EngraftmentINTRODUCTION
Acute lymphoblastic leukemia (ALL) is an aggres-
sive hematologic malignancy that affects both children
and adults. Although improvements in therapy have
led to dramatic increases in survival rates in children,
the majority of adults with ALL are not cured. Several
factors present at diagnosis of ALL have been corre-
lated with the outcome of chemotherapy without
stem cell transplantation (SCT) and are used clinically
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older age [1,2] and the presence and type of clonal
cytogenetic abnormalities [3]. A high WBC count at
diagnosis also has been identified as an independent
poor prognostic marker in ALL [4].
Patients with relapsed ALL may be offered alloge-
neic SCT provided that a suitable HLA-matched
donor is available and they meet basic eligibility
requirements for transplantation. Although SCT may
be routinely offered to patients with high-risk or
relapsed ALL, the optimal pretransplantation condi-
tioning regimen has not yet been defined. Favorable
results and equivalent survival rates have been reported
with myeloablative [5] and reduced-intensity [6,7]
conditioning regimens. A recent large, international
study reported a 5-year overall survival (OS) of 41% af-
ter induction and allogeneic SCT in patients with Phil-
adelphia chromosome–negative high-risk ALL [8].
Five-year OS for those with Philadelphia chromo-
some–positive ALL undergoing SCT in complete
remission (CR) are 44% for recipients of matched
sibling donor grafts and 35% for recipients of matched1921
1922 Biol Blood Marrow Transplant 18:1921-1926, 2012A. Daly et al.unrelated donor grafts [9]. In this report, we describe
our experience with the use of a myeloablative regimen
consisting of fludarabine, busulfan, and low-dose total
body irradiation (TBI) previously shown to have low
treatment-related mortality (TRM) in adults with
acute leukemia (primarily acute myelogenous leuke-
mia [AML]) [10] in a series of patients with high-risk
or relapsed ALL.PATIENTS AND METHODS
Between May 2000 and June 2008, a total of 44
patients age .18 years underwent SCT for ALL
(Foothills Medical Center, Calgary, Alberta, Canada)
while in first CR (CR1) with high-risk features
(n 5 32) or in second CR (CR2) (n 5 12). Patients
were eligible for SCT if a suitable related (n 5 25) or
unrelated (n 5 19) donor was identified (matched in
8 of 10 HLA alleles), or if a suitable cord blood (CB)
unit (n 5 1) was available. Patients considered for
SCT broadly had adequate performance status (East-
ern Cooperative Oncology Group performance status
0, 1, or 2) and organ function (left ventricular ejection
fraction.40%, creatinine clearance.40% of normal,
forced expiratory volume in 1 second .50% of
predicted, no uncontrolled infections, no evidence of
cirrhosis or advanced hepatic fibrosis) to undergo the
procedure. Patients age.65 years were not considered
for SCT.
Pretransplantation conditioning consisted of
fludarabine1 busulfan1 TBI in all cases. Intravenous
busulfan dosing was guided by pharmacokinetics in
29 patients. In these patients, the dose was determined
based on the results of a test dose (0.8 mg/kg) given on
day 27 before SCT, with subsequent doses adjusted
to target a busulfan exposure of 5000mM$min if the pre-
dicted exposure was .6000 mM$min. Given the high
rate of TRM observed at busulfan exposures .6000
mM$min, the busulfan doses were never increased [10].
Busulfan levels were measured by HPLC as described
previously [12]. Fludarabine 50 mg/m2/day i.v. was
administered on days 26 to 22, and busulfan 3.2
mg/kg/day i.v. was administered on days 25 to 22.
TBI comprised 400 cGy administered in 2 fractions
on day 21 or 0 (before stem cell infusion), depending
on Department of Radiation Oncology scheduling.
All patients received prophylaxis for graft-versus-
host disease (GVHD) in the form of antithymocyte
globulin (ATG; Thymoglobulin; Genzyme, Cam-
bridge,MA) 4.5 mg/kg administered in 3 divided doses
on days 22, 21, and 0. Pharmacologic prophylaxis
consisted of cyclosporine and short-course methotrex-
ate, followed by leukovorin rescue [13]. Cyclosporine
was tapered and discontinued by 3-6 months in pa-
tients with no clinical evidence of GVHD.Methotrex-
ate was not given to the CB transplant recipient.Antiviral prophylaxis with acyclovir was given for
at least 6 months posttransplantation. First-line pro-
phylaxis for Pneumocystis jiroveci was trimethoprim-
sulfamethoxazole for at least 6 months, with the option
of dapsone or pentamidine in patients with allergy or
intolerance to first-line prophylaxis. Patients with ris-
ing levels of cytomegalovirus (CMV) pp65 antigen or
CMV DNA measurement (based on immunofluores-
cence antigenemia assay or quantitative CMV PCR)
were offered preemptive treatment with ganciclovir
or valganciclovir, as described previously [14]. Anti-
fungal prophylaxis and colony-stimulating factors
were not routinely provided.
Thedayofneutrophil engraftmentwasdefined as the
first day of an absolute neutrophil count $0.5  109/L
(500/mm3) in 3 consecutive laboratory measurements
obtained on different days. Platelet recovery was
defined as the first of 3 consecutive laboratory val-
ues $20  109/L obtained on different days, with no
platelet transfusions within the previous 7 days. For
patients whose platelet counts never dropped below
20  109/L, the day of SCT was considered the day of
engraftment. Comorbidities were scored using the
Hematopoietic Stem Cell Transplantation Comorbi-
dity Index (HCT-CI) described by Sorror et al. [15].
We compared summary statistics (withmedian and
range) used to describe the cohort with the Mann-
Whitney U test. Kaplan-Meier estimates of OS and
progression-free survival (PFS) and cumulative inci-
dence statistics (nonrelapse mortality [NRM], engraft-
ment, GVHD) were calculated as described previously
[16]. These estimates were compared using the log-
rank (Mantel-Cox) statistic. Statistical calculations
were made using Prism Version 5.0 (GraphPad Soft-
ware, San Diego, CA).RESULTS
Table 1 summarizes the clinical and biological
features of the cohort at the time of SCT. Median
follow-up of surviving patients was 4.3 years (range,
1.0-9.0 years).
Engraftment and GVHD
All patients engrafted neutrophils and platelets.
The median time to neutrophil engraftment was
14 days (range, 11-28 days), and the median time to
platelet engraftment was 18 days (range, 0-105 days).
The recipient of a CB stem cell transplant engrafted
neutrophils on day 16 and platelets on day 45. Four
patients did not require platelet transfusions; these 4
patients achieved a median platelet count nadir of
24  109/L (range, 22-34  109/L), at a median of
11 days (range, 10-12 days) after transplantation.
Figure 1 shows the onset of acuteGVHD(aGVHD)
and chronic GVHD (cGVHD). The incidence of grade
Table 1. Patient Characteristics at Time of SCT
CR1, High-Risk
(n 5 32) CR2 (n 5 12)
Age, years, median (range) 40 (19-64) 25 (19-65)*
Donor, n
Matched related 17 3
Mismatched related 3 1
Matched unrelated 10 6
Mismatched unrelated 2 1
Umbilical cord 0 1
Graft type, n
Bone marrow 4 1
Peripheral blood stem cells 28 10
Umbilical CB 0 1
Time from diagnosis to SCT, months,
median (range)
4.2 (2.1-6.9) 48.7 (5.2-88.5)*
Cytogenetics, n
Normal 4 5
Hyperdiploid - 1
Near triploid 1 -
t(9;22) 16 -
t(4;11) 2 1
Complex 1 2
Other structural 4 1
Not available 4 2
Age >35 years, n† 10 1
High WBC count, n† 2 -
HCT-CI $1, n 9 4
*P < .05.
†Includes only those patients whose only high-risk feature at diagnosis
was age >35 years or an elevated WBC count.
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Figure 1. Time to onset of first manifestations of aGVHD and cGVHD
for patients undergoing SCTafter fludarabine 1 busulfan 1 TBI condi-
tioning and ATG 1 cyclosporine 1 methotrexate GVHD prophylaxis.
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Figure 2. PFS andOS from time of transplantation for ALL patients un-
dergoing SCTafter fludarabine1 busulfan1 TBI conditioning. Five-year
PFS was 56.7%.
Biol Blood Marrow Transplant 18:1921-1926, 2012 1923Conditioning in ALLII-IV aGVHD was 53.2%, and that of grade III-IV
aGVHD was 20.6%. Only 2 patients (4.5%) developed
aGVHD after day 60 post-SCT, one on day 99 and the
other on day 110. Chronic GVHD complicated 57% of
SCTs, occurring in 40.4% of recipients of a related do-
nor transplant and in 66.1%of recipients of an unrelated
donor transplant (P 5 .10). The mode of onset of
cGVHDwas progressive in 6 cases, quiescent in 3 cases,
and de novo in 11 cases. cGVHDwas of limited stage in
5 patients and extensive in 13 patients. Two patients
were lost to follow-up, and their cGVHD staging is un-
known. Twenty patients (45%) were treated with sys-
temic immunosuppressive therapy for GVHD for
a median of 360 days (range, 35-1702 days). All cases
of cGVHD developed within 1 year of SCT.
Busulfan Exposure
The pharmacokinetics of busulfan was assessed in
8 patients undergoing SCT in CR2 and in 21 patients
undergoing SCT in CR1 with high-risk disease. The
median busulfan area under the receiver-operating
characteristic curve (AUC) value was 4247 mM$min
(range, 3284-7794 mM$min) for patients in CR2 and
4662 mM$min (range, 3051-5844 mM$min) for pa-
tients in CR1with high-risk disease (P5 .42). Busulfan
exposure was not affected by age or weight at the time
of SCT. A tendency toward improved OS and PFS was
noted for patients with a busulfan AUC value belowthe median value (4660 mM$min) (hazard ratio [HR],
0.31; 95% confidence interval [CI], 0.093-1.06;
P 5 .06 for both OS and PFS).
Survival
PFS and OS are shown in Figure 2. Five-year PFS
was 56.7%, with no difference between patients under-
going SCT for high-risk disease in CR1 and those
undergoing SCTwhile in CR2 (P5 .80). Two patients
1924 Biol Blood Marrow Transplant 18:1921-1926, 2012A. Daly et al.remained alive after undergoing a second SCT for
relapsed disease. Five-year OS was 66%, once again
with no difference between patients undergoing SCT
in CR1 and those undergoing SCT in CR2.
Seven patients died of recurrent ALL at a median
of 365 days (range, 62-2989 days) after SCT. Eight
patients died without relapse, at a median of 71 days
(range, 14-152 days) after SCT. Causes of NRM
include multiorgan failure (n 5 5) and infection
(n 5 3). Infectious causes of death include 1 case of
CMV, 1 case of Epstein-Barr virus–positive post-
SCT lymphoproliferative disorder (before the avail-
ability of rituximab for this indication), and 1 case of
bacterial sepsis in the setting of steroid-refractory
aGVHD. Grade II-IV aGVHD was not associated
with increased mortality, occurring in 10 of 15 pati-
ents who died and in 20 of 29 patients who survived
(P 5 not significant).
TRM was significantly influenced by age and
comorbidity at the time of SCT. Patients with TRM
and those with multiorgan failure/ARDS were signifi-
cantly older than survivors (median, 49 years [range,
23-65 years] versus 35 years [19-64 years]; P 5 .01,
and 53 years [47-65 years] versus 36 years [19-64
years]; P 5 .0058). Age .45 years was significantly
associated with 5-year NRM (3.4% versus 64.4%;
HR, 0.034; 95%CI, 0.0076-0.15; P\ .0001). This dif-
ference was especially striking in older patients with
comorbid medical conditions. Patients age .45 years
with an HCT-CI of 0 experienced significantly less
TRM than those with an HCT-CI $1 (HR, 0.15;
95%CI, 0.037-0.64; P5 .01). Comorbidity did not in-
fluence TRM (HR, 3.2; 95% CI, 0.011-940; P 5 .69)
or OS (HR, 0.53; 95% CI, 0.039-7.2; P 5 .23) in0 50 100 150
0
20
40
60
80
100
Age >45, no comorbidity
Age >45, with comorbidity
Age <45, no comorbidity
Age <45, with comorbidity
Overall Survival by Age and Comorbidity
Survival (months)
P
e
r
c
e
n
t
 
S
u
r
v
i
v
a
l
Figure 3. OS from time of transplantation for patients with ALL under-
going SCTafter fludarabine 1 busulfan 1 TBI conditioning.patients age\45 years. OS was significantly worse in
patients age.45 years with an HCT-CI$1 compared
with the rest of the cohort (HR, 0.15; 95% CI, 0.037-
0.64; P 5 .01) (Figure 3). In absolute terms, patients
age\45 years with an HCT-CI of 0 had a 5-year OS
of 70.6%, and those with an HCT-OS $1 had
a 5-year OS of 80%. For patients age.45 years, these
respective values were 62.5% and 12.5%.DISCUSSION
Although allogeneic SCT remains the treatment of
choice for patients with high-risk or relapsed ALL, the
optimal conditioning regimen for this procedure re-
mains unclear. Reduced-intensity regimens may result
in low rates of TRM [17], but are associated with sim-
ilar rates of PFS as obtained with more traditional
myeloablative regimens [18]. We have previously
shown that NRM and OS are correlated with busulfan
exposure for the fludarabine 1 busulfan regimen with
or without TBI in patients with various hematologic
malignancies [11]. The 36-month OS was 68% for
patients with a busulfan AUC value\6000 mM$min
and 23% for those with a busulfan AUC value
.6000 mM$min (P 5 .001). This suggests that for
this regimen, reducing exposure to severelymyelotoxic
agents may result in improved outcomes. Similar re-
sults were reported by Santarone et al. [19] using a sim-
ilar regimen without TBI, ATG only for SCT
recipients of unrelated donor grafts, and busulfan ex-
posure targeted to 5300 mM$min. In the present study,
we demonstrate NRM of 18.2%, which is similar to
rates reported with reduced-intensity conditioning
regimens [6,7,20]. Busulfan exposure did not
influence the outcome of transplantation in this small
group of patients, but we note a trend consistent
with our previous findings and those of others [21].
The success of fludarabine 1 busulfan regimens
with low-dose TBI or even no TBI raises the possibil-
ity of developing conditioning regimens for patients
with ALL without the long-term consequences of irra-
diation. In contrast, however, we have shown that the
addition of TBI to fludarabine and busulfan reduced
the relapse rate without increasing TRM in patients
with AML receiving ATG [10]. In this case, TBI
may be compensating for an adverse effect of ATG
on relapse, while the beneficial effects on TRM and
quality of life are maintained.
GVHD remains the major cause of NRM after al-
logeneic SCT [22]. GVHD rates are affected by ge-
netic (particularly HLA) disparity between donor and
recipient, by stem cell source, and by conditioning reg-
imen. The addition of ATG to standard pretransplan-
tation conditioning has previously been shown to
reduce rates of severe aGVHD and extensive cGVHD
without changing TRM [23-25]. These results were
recently confirmed when it was demonstrated that
Biol Blood Marrow Transplant 18:1921-1926, 2012 1925Conditioning in ALLthe addition of low-dose ATG to standard condition-
ing reduced the rate of grade II-IV aGVHD from
29% to 8% (P 5 .038) in a cohort of Korean AML
patients receiving predominantly bone marrow stem
cells [26]. Also, the addition of rabbit anti-Jurkat T
lymphoblast antibodies (Fresenius-ATG) to standard
GVHD prophylaxis was recently shown to reduce
the rate of cGVHD from 42.6% to 12.2% (P \
.0001) in a randomized, open-label, multicenter study
in the setting of SCT from matched unrelated donors
[25]. In the present cohort, the rate of grade II-IV
aGVHD was 53.2% and that of cGVHD was 57%.
These rates appear to be higher than those reported
in the aforementioned studies, possibly reflecting ef-
fects of recipient age, use of TBI, use of cytokine-
mobilized peripheral blood as the stem cell source,
and differing doses or types of ATG. The low rates
of GVHD-related mortality in our cohort and the rel-
atively short duration of therapy for cGVHD com-
pared with other published reports [26] may reflect
other beneficial effects of pretransplantation ATG as
well.
Regimen-related toxicity has traditionally re-
stricted eligibility for myeloablative SCT to younger
recipients. In many cases, older patients are treated
with reduced-intensity or nonmyeloablative condi-
tioning regimens, which are associated with lower
regimen-related morbidity and mortality [17] com-
pared withmyeloablative conditioning. The exact ben-
efits of this approach have been difficult to
demonstrate, however, because in many cases OS and
PFS are similar to those of patients receiving myel-
oablative conditioning [18,20]. In our cohort, OS
was significantly worse for patients age .45 years
with comorbid medical conditions. This effect is
related primarily to increased TRM in these patients,
and it is possible that reducing the intensity of
conditioning for this population may translate into
improved OS.
It is important to emphasize the limitations of this
single-center report. We describe a relatively small
number of patients, treated over a period of several
years. Although we noted a substantial difference in
outcome for older patients with comorbid health con-
ditions, we believe that these results should be inter-
preted cautiously, and ultimately the question should
be examined in a larger number of patients.
In conclusion, we report excellent long-term out-
comes for young patients with high-risk or relapsed
ALL who undergo SCT after fludarabine 1
busulfan 1 TBI conditioning. The OS and disease-
free survival rates that we report compare favorably
with those reported in larger series of 50% at 2 years
and 39% at 5 years [27,28]. Older patients without
comorbidities had similar survival to that of
younger patients, whereas those with comorbidities
experienced high rates of TRM. In conclusion, thisregimen has been shown to be a safe and effective
treatment for ALL and should be studied further in
larger patient cohorts. The effects of age and
comorbidity should be examined carefully to
determine whether this regimen is suitable for this
subset of potential SCT recipients.ACKNOWLEDGMENTS
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